Loading clinical trials...
Loading clinical trials...
Randomized Phase 2 Trial Of AG013736 Or Bevacizumab In Combination With Paclitaxel And Carboplatin As First Line Treatment For Patients With Advanced Non Small Cell Lung Cancer
To determine if the addition of AG-013736 to chemotherapy is beneficial in patients with advanced lung cancer who have not been previously treated.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Pfizer Investigational Site
Baton Rouge, Louisiana, United States
Pfizer Investigational Site
Pittsfield, Massachusetts, United States
Pfizer Investigational Site
Columbus, Mississippi, United States
Pfizer Investigational Site
Corinth, Mississippi, United States
Pfizer Investigational Site
New Albany, Mississippi, United States
Pfizer Investigational Site
Oxford, Mississippi, United States
Pfizer Investigational Site
Southaven, Mississippi, United States
Pfizer Investigational Site
Tupelo, Mississippi, United States
Pfizer Investigational Site
Lincoln, Nebraska, United States
Pfizer Investigational Site
Cleveland, Ohio, United States
Start Date
April 1, 2008
Primary Completion Date
April 1, 2011
Completion Date
October 1, 2012
Last Updated
November 8, 2013
118
ACTUAL participants
Bevacizumab
DRUG
Carboplatin
DRUG
Paclitaxel
DRUG
AG-013736 (axitinib)
DRUG
Carboplatin
DRUG
Paclitaxel
DRUG
Lead Sponsor
Pfizer
NCT05691465
NCT06696768
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions